Price (delayed)
$1.4
Market cap
$79.33M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.27
Enterprise value
$60.85M
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond ...
Highlights
Black Diamond Therapeutics's EPS has increased by 32% YoY and by 4.5% QoQ
The net income has grown by 15% YoY and by 4.7% from the previous quarter
The company's equity fell by 29% YoY and by 15% QoQ
The quick ratio has contracted by 28% YoY and by 12% from the previous quarter
Key stats
What are the main financial stats of BDTX
MarketValuationsEarnings
Shares outstanding
56.66M
Market cap
$79.33M
Enterprise value
$60.85M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.95
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$78.78M
Net income
-$69.68M
EBIT
-$69.68M
EBITDA
-$69.33M
Free cash flow
-$62.21M
Per shareBalance sheetLiquidity
EPS
-$1.27
EPS diluted
-$1.27
Free cash flow per share
-$1.13
Book value per share
$1.47
Revenue per share
$0
TBVPS
$2.23
Total assets
$122.64M
Total liabilities
$39.36M
Debt
$18.78M
Equity
$83.29M
Working capital
$80.6M
Debt to equity
0.23
Current ratio
4.92
Quick ratio
4.83
Net debt/EBITDA
0.27
MarginsEfficiencyDividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-50.4%
Return on equity
-70.4%
Return on invested capital
-64%
Return on capital employed
-68.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BDTX stock price
How has the Black Diamond Therapeutics stock price performed over time
Intraday
-7.28%
1 week
-13.04%
1 month
-22.65%
1 year
-72.6%
YTD
-34.58%
QTD
-9.68%
Financial performance
How have Black Diamond Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$78.78M
Net income
-$69.68M
Gross margin
N/A
Net margin
N/A
BDTX financials
The net income has grown by 15% YoY and by 4.7% from the previous quarter
BDTX's operating income is up by 9% YoY and by 3.2% QoQ
Growth
What is Black Diamond Therapeutics's growth rate over time
BDTX growth chart
Valuation
What is Black Diamond Therapeutics stock price valuation
P/E
N/A
P/B
0.95
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Price to earnings (P/E)
Black Diamond Therapeutics's EPS has increased by 32% YoY and by 4.5% QoQ
Price to book (P/B)
The P/B is 57% lower than the last 4 quarters average of 2.2 and 47% lower than the 5-year quarterly average of 1.8
The company's equity fell by 29% YoY and by 15% QoQ
Price to sales (P/S)
Efficiency
How efficient is Black Diamond Therapeutics business performance
BDTX's return on invested capital is up by 19% year-on-year
The ROA rose by 10% YoY
Black Diamond Therapeutics's ROE has increased by 8% YoY but it has decreased by 3.4% from the previous quarter
Dividends
What is BDTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BDTX.
Financial health
How did Black Diamond Therapeutics financials performed over time
Assets vs liabilities
BDTX's current ratio is down by 28% year-on-year and by 11% since the previous quarter
The quick ratio has contracted by 28% YoY and by 12% from the previous quarter
Debt vs equity
The debt is 77% smaller than the equity
The company's equity fell by 29% YoY and by 15% QoQ
Black Diamond Therapeutics's debt to equity has increased by 21% YoY and by 15% QoQ
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.